MANCHESTER, England, Nov. 12, 2024 /PRNewswire/ -- Smartkem (Nasdaq: SMTK), positioned to power the next generation of displays using its disruptive organic thin-film transistors (OTFTs), today provides a business update and reports financial results for the three and nine months ended September 30, 2024.

Smartkem Chairman and CEO, Ian Jenks, commented:

"During the third quarter of 2024, we continued to gain traction in our drive to commercialize our proprietary semiconductor materials, which enable flexible, transparent and lightweight microLED displays. In September, we entered into a joint development agreement with Chip Foundation to develop microLED-based backlight technology for LCDs, further expanding our ongoing collaborations with leading display manufacturers. In addition, ITRI has requested Smartkem apply our innovations to develop packaging solutions for advanced computer and AI chips.

"Together with our developmental partners, our printable semiconductor inks have the potential to solve a number of microLED display manufacturing challenges using flexible plastic substrates and low temperature processes. We believe our organic transistor technology has the potential to catalyze the microLED display industry, which is expected to grow from $150 million in revenue in 2024 to over $4 billion by 2031^[1].

"Looking into 2025, we are focused on delivering qualifications and design wins on existing and new collaborations as we seek to increase the adoption of advanced display technologies using our technology," concluded Jenks.

Recent Business Highlights

Signed a JDA with Shanghai Chip Foundation Semiconductor Technology Co., to co-develop a new generation of microLED-Based backlight technology for Liquid Crystal Displays
Presented keynote at the PlayNitride 2024 MicroLED Technology Forum, where we demonstrated the inherent advantages and inevitability of microLED display mass adoption, including high durability, extremely strong brightness, de-coupled production processing, and high aperture ratio.
Demonstrated our leadership in organic transistor technology:
- Exhibited at SEMICON® Taiwan 2024.
- Delivered presentation titled "Chip-First Active-Matrix Fabrication Approach Improves Transistor Connectivity to Micro-LEDs for Higher Yielding Displays" and exhibited at the 24^th International Meeting on Information Display (IMID) 2024 in Korea.
- Presented "Developing Flexible Integrated Circuits Through Customized Organic TFTs" at The International Conference on Flexible and Printed Electronics (ICFPE) 2024.
- Exhibited at TechBlick: The Future of Electronics Reshaped global conference in Berlin.
- Exhibited at the 6^th National Conference on Organic Field-Effect Transistors in Hangzhou, China.

^[1] 2024 Omdia Report

Q3 2024 Financial Highlights:

Cash and cash equivalents were $1.8 million as of September 30, 2024, compared to $8.8 million as of December 31, 2023.
Operating expenses were $3.0 million for the three months ended September 30, 2024, compared $2.7 million for the same period of 2023.
Revenues were nil for the three months ended September 30, 2024, compared to $3 thousand for the same period of 2023 in which the company sold OTFT backplanes and TRUFLEX materials for customer assessment and development costs.

About Smartkem

Smartkem is seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that have the potential to drive the next generation of displays. Smartkem's patented TRUFLEX® liquid semiconductor polymers, can be used to make a new type of transistor that can be used in a number of display technologies, including next generation microLED displays. Smartkem's inks enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost displays that outperform existing models.

Smartkem develops its materials at its research and development facility in Manchester, UK and its semiconductor manufacturing processes at the Centre for Process Innovation (CPI) at Sedgefield, UK. It has a field application office in Taiwan. The company has an extensive IP portfolio including 125 granted patents across 19 patent families and 40 codified trade secrets. For more information, visit: www.smartkem.com and follow us on LinkedIn www.linkedin.com/company/smartkem-limited.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Smartkem's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on Smartkem Inc.'s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or elated expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

                                                                                   
            
              SMARTKEM, INC.


                                                                             
            Condensed Consolidated Balance Sheets


                                                                                    
            
              (Unaudited)


                                                                  
            (in thousands, except number of shares and per share data)






                                                                                                                                                 September 30,               December 31,


                                                                                                                                            2024                    2023


                                                                                                                                                 (Unaudited)



            
              Assets



            Current assets



            Cash and cash equivalents                                                                                                $
         1,783              $
         8,836



            Accounts receivable                                                                                                                                        268



            Research and development tax credit receivable                                                                                  1,163                       610



            Prepaid expenses and other current assets                                                                                         804                       811



            Total current assets                                                                                                            3,750                    10,525



            Property, plant and equipment, net                                                                                                353                       455



            Right-of-use assets, net                                                                                                          197                       285



            Other assets, non-current                                                                                                           6                         7



            
              Total assets                                                                                                  $
         4,306             $
         11,272





            
              Liabilities and stockholders' equity



            Current liabilities



            Accounts payable and accrued expenses                                                                                    $
         1,463              $
         1,178



            Lease liabilities, current                                                                                                        165                       230



            Other current liabilities                                                                                                         367                       360



            Total current liabilities                                                                                                       1,995                     1,768



            Lease liabilities, non-current                                                                                                     31                        19



            Warrant liability                                                                                                                                        1,372



            Total liabilities                                                                                                               2,026                     3,159





            Commitments and contingencies (Note 7)





            
              Stockholders' equity:



            Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized,
    856 and 13,765 shares issued and outstanding, at September 30, 2024 and
    December 31, 2023, respectively



            Common stock, par value $0.0001 per share, 300,000,000 shares authorized,
    1,780,472 and 889,668 shares issued and outstanding, at September 30, 2024
    and December 31, 2023, respectively



            Additional paid-in capital                                                                                                    113,374                   104,757



            Accumulated other comprehensive loss                                                                                          (1,297)                  (1,578)



            Accumulated deficit                                                                                                         (109,797)                 (95,066)



            Total stockholders' equity                                                                                                      2,280                     8,113



            
              Total liabilities and stockholders' equity                                                                    $
         4,306             $
         11,272

                                                                                           
              
                SMARTKEM, INC.


                                                                      
              Condensed Consolidated Statements of Operations and Comprehensive Loss


                                                                                             
              
                (Unaudited)


                                                                            
              (in thousands, except number of shares and per share data)






                                                                                                                                                     Three Months Ended September
                                                                                                                                                                     30,                                 Nine Months Ended September 30,


                                                                                                                                                 2024                                 2023            2024                                  2023



     Revenue                                                                                                        
              $                                                 $
            3      $
            40                          $
              27



     Cost of revenue                                                                                                                                                                       1                32                                      23



     Gross profit                                                                                                                                                                          2                 8                                       4





     Other operating income                                                                                                                        287                                    257               725                                     695





     Operating expenses



     Research and development                                                                                                                    1,504                                  1,568             3,938                                   4,104



     Selling, general and administrative                                                                                                         1,578                                  1,268             4,784                                   4,025



     (Gain)/loss on foreign currency transactions                                                                                                   43                                    118                75                                     186



     Total operating expenses                                                                                                                    3,125                                  2,954             8,797                                   8,315





     Loss from operations                                                                                                                      (2,838)                               (2,695)          (8,064)                                (7,616)





     Non-operating income/(expense)



     Gain/(loss) on foreign currency transactions                                                                                                                                      (787)            (249)                                    248



     Transaction costs allocable to warrants                                                                                                                                                                                                   (198)



     Change in fair value of the warrant liability                                                                                                                                       458               672                                     461



     Interest income/(expense)                                                                                                                     (4)                                     2                 5                                       8



     Total non-operating income/(expense)                                                                                                          (4)                                 (327)              428                                     519





     Loss before income taxes                                                                                                                  (2,842)                               (3,022)          (7,636)                                (7,097)



     Income tax expense                                                                                                                                                                                   (1)



     Net loss                                                                                                                      $
              (2,842)                       $
          (3,022)  $
          (7,637)                       $
           (7,097)





     Net loss                                                                                                                      $
              (2,842)                       $
          (3,022)  $
          (7,637)                       $
           (7,097)



     Other comprehensive loss:



     Foreign currency translation                                                                                                                  125                                    850               281                                   (123)



     Total comprehensive loss                                                                                                      $
              (2,717)                       $
          (2,172)  $
          (7,356)                       $
           (7,220)





     Common share data:



     Basic net loss per common share*                                                                                               $
              (0.86)                        $
          (1.78)   $
          (2.49)                        $
           (5.82)



     Diluted net loss per common share*                                                                                             $
              (0.86)                        $
          (1.78)   $
          (4.80)                        $
           (5.82)



     Dividend per common share                                                                                      
              $                              
              $                     $
          (2.31)        
              $





     Weighted average number of basic shares outstanding*                                                                                    3,308,975                              1,701,166         3,068,110                               1,219,450



     Weighted average number of diluted shares outstanding*                                                                                  3,308,975                              1,701,166         3,068,110                               1,219,450





      * reflects a one-for-thirty-five (1:35) reverse stock split effected on September 21, 2023

View original content:https://www.prnewswire.co.uk/news-releases/smartkem-reports-third-quarter-2024-financial-results-302301409.html

Tags

More Like This

Smartkem Reports Second Quarter 2024 Financial Results

Smartkem Reports Fourth Quarter and Full Year 2024 Financial Results

Smartkem Reports Fourth Quarter and Full Year 2023 Financial Results

Smartkem Recaps 2024 Achievements and Sets 2025 Goals

SMARTKEM, INC. MICRO-LED DISPLAY PAPER PUBLISHED IN LEADING SCIENCE JOURNAL, NATURE COMMUNICATIONS

Smartkem to Present and Exhibit at MicroLED Connect 2024

Smartkem to Present at the PlayNitride 2024 MicroLED Technology Forum and Exhibit at SEMICON® Taiwan 2024

Smartkem To Exhibit and Present at Display Week 2024